Seems to me like we're not that close to having "widespread support" in the general public for tackling aging, so I'm curious to know why you think this will change in the near future. Is it just that attitudes will change once everyone realizes how close to reality it is, rather than crazy sci-fi?
Isn't regulation also a problem here? That is, aging is not considered a disease in and of itself, making it difficult to authorize any human clinical trials? I thought it was necessary for SENS to piggy-back off of treatments for officially recognized diseases caused by aging. But I've been reading a book from 2007 about this stuff, so it's possible all that is completely out of date now.
Edit: sorry missed your last bit about regulation. I suppose with big-pharma lobbying, that could be cleared up easily enough, given the profit potential you mention.
http://www.nature.com/news/anti-ageing-pill-pushed-as-bona-f...
Best of all, for all it does, generic Metformin/glucophage is DIRT CHEAP, even in the USA.
I wouldn't be so sure. They have the science, but do they have product leads? If not, that could take a few years alone. Then tack on all the pre-clinical testing.
The average drug takes ~8 years once it's discovered to get approved by the FDA. And that's if nothing goes wrong.
See my post in this thread about how they admit not being properly blinded, and also decided in some unspecified way when a mouse was "moribund" at which point the mouse was killed. The former is maybe ok (shit happens), but the lack of details regarding "moribund" are unacceptable. For that info to be missing, we can deduce this paper was not approved by a honest/competent group of reviewers.
And it's sort of mean to say that my naive response to this SENS stuff is "slowing down actual progress."
Maybe the first, certainly not the second.
There's an unfortunate correlation between sloppy science and popular journals that's been shown again and again. Nature is one of the journals with the highest rates of retractions[1]. Thinking "it's been published in Nature, it must be good science" is certainly not reasonable in any way.
What does that have to do with the quality of this paper?
>'And it's sort of mean to say that my naive response to this SENS stuff is "slowing down actual progress."'
Sorry for that, it is not really your fault, rather the fault of those involved in the publication of this paper. But don't shoot the messenger, it is also not my fault this study was apparently poorly peer reviewed yet got a bunch of press coverage. I just wish people were doing their jobs and acting with proper skepticism because I want medical research to be successful.
It would be nice if this were true and we could have a easy to use heuristic. But, as pointed out by others, the evidence seems to point to either no, or even an inverse, relationship between journal prestige/respect and the quality of peer review and journal articles.
https://news.ycombinator.com/item?id=8838073 (394 days)
https://news.ycombinator.com/item?id=9592378 (256 days)
https://news.ycombinator.com/item?id=6406084 (868 days)
https://news.ycombinator.com/item?id=9844909 (211 days)
https://news.ycombinator.com/item?id=8727314 (420 days)
https://news.ycombinator.com/item?id=10468025 (98 days)
https://news.ycombinator.com/item?id=9613206 (252 days)
http://sens.org/research/introduction-to-sens-research/death...
The SENS Research Foundation has for some years funded work on clearing senescent cells at the Campisi lab, and Judith Campisi is one of the people involved in Union Biotechnology, the company commercializing therapies created from the study discussed here. Senescent cell clearance was advocated and funded by SENS advocates and organizations long before the rest of the scientific community caught up. It has been a long slog to get to the tipping point, and here we are, being proved right.
So, you know, slightly relevant.
http://finance.yahoo.com/news/unity-biotechnology-launches-f...
The technology being used here in mice is not suitable for humans in its present form. But it won't take much tinkering to make it so - this is an age of gene therapy. The most important things here are that:
(a) a robust life extension was achieved with a SENS approach of damage repair, something that SENS advocates have been working towards for more than a decade. The SENS view is right. It is right today, as demonstrated, and it was right ten years ago when people were lining up to deride it. A SENS technology has produced a robust life extension and remediation of age-related diseases across the board in normal mice. People who think that SENS and damage repair are not the way forward need to take a long, serious look at why they think that, and then revisit the science.
(b) The Union Biotech VC and university PR machines are putting out word for word the SENS vision of damage repair to treat aging. SENS has won. This is the dawn of the age of rejuvenation biotechnology, with a near future of widespread support for that goal.
(c) There are at least three methods of clearing senescent cells in mammals, and most likely four. (1) The method of Oisin Biotechnology, seed funded last year by Methuselah Foundation and SENS Research Foundation, (2) the senolytic drug combination demonstrated last year, (3) the capase/gene trigger work linked here, and (4) the adaptation of method #3 currently underway at Union Biotechnology.
To be clear, half of these methods work in mammals now. If you had the right connections you could use them today. Clinical availability will not be a long time in coming, and I for one hope to see this escape the regulatory gauntlet very rapidly and get into medical tourism and clinics worldwide just like stem cell therapies did at the turn of the century.
Finally a note for investors and business people: every SENS rejuvenation technology of this ilk has a target market of every human being on the planet over the age of 30. Everyone, with treatments once every decade at a minimum. This is medicine that will make blockbuster drugs of past years look like damp squibs. That is why this should and will escape the narrow regulatory gauntlet that will try to restrict use to old people with the late stage of a few specific illnesses. That is nonsense and no way to run the future - senescent cells should be periodically cleared every few years starting at 30.